Communiqués Satellos Bioscience Inc.

Actions

MSCL

CA80401L8033

Recherche biotechnologique et médicale

Marché Fermé - Toronto S.E. Autres places de cotation 21:56:03 13/07/2026			Varia. 5j.	Varia. 1 janv.
12,85 ^CAD	-5,03%		+11,16%	+62,25%

08/07	Satellos Bioscience Inc. publie les données intermédiaires à six mois de l'étude TRAILHEAD sur le SAT-3247 chez des adultes atteints de la dystrophie musculaire de Duchenne	CI
08/07	Satellos : les données intérimaires de phase 2 montrent que le SAT-3247 améliore les mesures musculaires chez les adultes atteints de DMD	MT

Communiqués

08/07	Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247	AQ
29/06	Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy	AQ
25/06	Satellos to Present Clinical Program Updates at ICNMD 2026	AQ
17/06	Satellos Bioscience Announces Results of Annual Meeting of Shareholders	AQ
27/05	Satellos to Participate in Upcoming Investor Conferences	AQ
15/05	Satellos Bioscience : First Quarter 2026 Financial Results and Operational Highlights	PU
15/05	Satellos Bioscience : First Quarter 2026 Management’s Discussion Analysis	PU
15/05	Satellos Bioscience: Q1 Earnings Snapshot	AQ
15/05	Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress	AQ
05/05	Investor Presentation 04/22/2026 00:00:00	PU
23/04	Satellos Bioscience : 2026 Bloom Burton & Co. Healthcare Investor Conference Presentation	PU
09/04	Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference	AQ
30/03	Satellos Reports 2025 Financial Results and Highlights Recent Company Progress	AQ
27/03	Satellos Bioscience: Q4 Earnings Snapshot	AQ
27/03	Satellos Bioscience : Fourth Quarter 2025 Financial Results and Operational Highlights	PU
27/03	Satellos Bioscience : Fourth Quarter 2025 Management’s Discussion Analysis	PU
27/03	Satellos Reports 2025 Financial Results and Highlights Recent Company Progress	AQ
10/03	Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference	AQ
24/02	Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference	BU
18/02	Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy	BU
17/02	Satellos to Participate in Upcoming Investor Conferences	BU
12/02	Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy	BU
10/02	Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026	BU
09/02	Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares	BU
06/02	Canadian Investment Regulatory Organization Trade Resumption - MSCL	AQ